Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.
He brings more than 20 years of experience in the pharmaceutical industry ranging from sales and marketing leadership, general management and joint venture leadership in several therapeutic areas, including oncology, rheumatology, dermatology and primary care. Prior to joining Spectrum, Keller spent 21 years at Amgen. His most recent role was vice president and general manager, bone health business unit, Amgen. During his career at Amgen, Keller has been the marketing lead or the general manager for four of the world's top selling biologic medicines Neupogen, Neulasta, Aranesp and Enbrel. He also has significant international experience, as managing director for Amgen's U.K. and Ireland affiliate.